{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04392206",
      "OrgStudyIdInfo": {
        "OrgStudyId": "19-007203"
      },
      "Organization": {
        "OrgFullName": "Mayo Clinic",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",
      "OfficialTitle": "A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 15, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 1, 2025",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 1, 2026",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 14, 2020",
      "StudyFirstSubmitQCDate": "May 14, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 18, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 9, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 12, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Albert Hakaim",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Mayo Clinic"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Albert Hakaim",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "End Stage Renal Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Adipose Derived Mesenchymal Stem Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Adipose Derived Mesenchymal Stem Cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Adipose Derived Mesenchymal Stem Cells",
            "InterventionDescription": "The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Adipose Derived Mesenchymal Stem Cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "AMSC"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of participants with treatment-related adverse events",
            "PrimaryOutcomeDescription": "Evaluate the safety of AMSC administration by assessing the number of participants to experience an adverse event as defined by inflammation, infection (local or systemic), aneurysm formation, clinically significant increase or decrease in blood flow or thrombosis formation as evaluated through physical exam and ultrasound.",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient between 18 and 85 years old\nPatient currently planned for creation of an upper extremity AV fistula with suitable anatomy\nAbility to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures\nLife expectancy of at least 24 months\nIf female, must be post-menopausal or not able to have children. Post-menopausal/non-child bearing status must be clearly documented in the medical record. If documentation of post-menopausal/non-child bearing status is not available then a pregnancy test must be performed.\n\nExclusion Criteria:\n\nMalignancy or treatment for malignancy within the previous 6 months\nImmunodeficiency including AIDS / HIV or Active autoimmune disease\nDocumented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events\nTreatment with any investigational drug/ device within 60 days prior to study entry or Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs and the AVF\nHistory of failed organ transplant on immunosuppression.\nSubjects with known active infection (infection which is being treated)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Elizabeth Starck",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(904) 953-7971",
            "CentralContactEMail": "Starck.Elizabeth@mayo.edu"
          },
          {
            "CentralContactName": "Mauricia Buchanan",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(904) 953-2077",
            "CentralContactEMail": "buchanan.mauricia@mayo.edu"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Albert Hakaim, MD",
            "OverallOfficialAffiliation": "Mayo Clinic",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Mayo Clinic in Florida",
            "LocationStatus": "Recruiting",
            "LocationCity": "Jacksonville",
            "LocationState": "Florida",
            "LocationZip": "32224",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Elizabeth Starck",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "904-953-7971",
                  "LocationContactEMail": "Starck.Elizabeth@mayo.edu"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Mayo Clinic Clinical Trials",
            "SeeAlsoLinkURL": "https://www.mayo.edu/research/clinical-trials"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007676",
            "ConditionMeshTerm": "Kidney Failure, Chronic"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007674",
            "ConditionAncestorTerm": "Kidney Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000051436",
            "ConditionAncestorTerm": "Renal Insufficiency, Chronic"
          },
          {
            "ConditionAncestorId": "D000051437",
            "ConditionAncestorTerm": "Renal Insufficiency"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M5627",
            "ConditionBrowseLeafName": "Constriction, Pathologic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9851",
            "ConditionBrowseLeafName": "Kidney Failure, Chronic",
            "ConditionBrowseLeafAsFound": "End Stage Renal Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M25871",
            "ConditionBrowseLeafName": "Renal Insufficiency",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25870",
            "ConditionBrowseLeafName": "Renal Insufficiency, Chronic",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}